Literature DB >> 2184372

Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients.

B Ensoli1, G Barillari, S Z Salahuddin, R C Gallo, F Wong-Staal.   

Abstract

Kaposi's sarcoma (KS) is frequently associated with human immunodeficiency virus-1 (HIV-1) infection. Supernatants from HIV-1-infected T cells carrying the CD4 antigen promote the growth of cells derived from KS lesions of AIDS patients (AIDS-KS cells), and the HIV-1 tat gene, introduced into the germ line of mice, induces skin lesions closely resembling KS. Here we report that the tat gene product (Tat) is released from both HIV-1-acutely infected H9 cells and tat-transfected COS-1 cells. These Tat-containing supernatants specifically promote growth of AIDS-KS cells which are inhibited by anti-Tat antibodies; recombinant Tat has the same growth-promoting properties. Therefore a viral regulatory gene product can be released as a biologically active protein and directly act as a growth stimulator. These and previous data indicate that extracellular Tat could be involved in the development or progression, or both, of KS in HIV-1-infected individuals.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2184372     DOI: 10.1038/345084a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  227 in total

1.  Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine.

Authors:  R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

2.  Role for human immunodeficiency virus type 1 Tat protein in suppression of viral reverse transcriptase activity during late stages of viral replication.

Authors:  M Kameoka; L Rong; M Götte; C Liang; R S Russell; M A Wainberg
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

Review 3.  Epidemiological evidence and molecular basis of interactions between HIV and JC virus.

Authors:  J R Berger; A Chauhan; D Galey; A Nath
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

4.  Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.

Authors:  Christoph Rader; Subhash C Sinha; Mikhail Popkov; Richard A Lerner; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

5.  Selective up-regulation of functional CXCR4 expression in erythroid cells by HIV-1 Tat protein.

Authors:  D Gibellini; M C Re; F Vitone; N Rizzo; C Maldini; M La Placa; G Zauli
Journal:  Clin Exp Immunol       Date:  2003-03       Impact factor: 4.330

6.  Interleukin-8 and growth-regulated oncogene alpha mediate angiogenesis in Kaposi's sarcoma.

Authors:  Brian R Lane; Jianguo Liu; Paul J Bock; Dominique Schols; Michael J Coffey; Robert M Strieter; Peter J Polverini; David M Markovitz
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

7.  Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1.

Authors:  H Xiao; C Neuveut; H L Tiffany; M Benkirane; E A Rich; P M Murphy; K T Jeang
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

8.  Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene.

Authors:  G Altavilla; A Caputo; M Lanfredi; C Piola; G Barbanti-Brodano; A Corallini
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

9.  Oncostatin-M stimulates tyrosine protein phosphorylation in parallel with the activation of p42MAPK/ERK-2 in Kaposi's cells. Evidence that this pathway is important in Kaposi cell growth.

Authors:  M C Amaral; S Miles; G Kumar; A E Nel
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

10.  Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein.

Authors:  T C Rodman; S E To; H Hashish; K Manchester
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.